IGNT "Photo Release — Ingen at Home Plate Ready to Catch Sales of $10M in 2010 and $50M in 2012"

W.W.

INGEN TECHNOLOGIES, INC.

Stock Symbol : IGNT

INGEN TECHNOLOGIES, INC.

Stock Symbol : IGNT

Photo Release — Ingen at Home Plate Ready to Catch Sales of $10M in 2010 and $50M in 2012

YUCAIPA, Calif., Nov. 23, 2009 (GLOBE NEWSWIRE) — Ingen Technologies, Inc. (Pink Sheets:IGNT – News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries announced today that expected sales projections for 2010 and 2012 are on target.

Symbol	Price	Change
IGNT.PK	0.0029	+0.0001

Photos accompanying this release are available at http://www.globenewswire.com/newsroom/prs/?pkgid=6868 and http://www.globenewswire.com/newsroom/prs/?pkgid=6869

The company’s ISO Certification in December 2009 also allows Ingen to begin shipping product of its new Oxyview Nasal Cannula and Oxyview to China, Europe, Australia, Japan and Canada. Export sales will represent the majority of our $10M in 2010, and by 2012 reach $50M.The company’s ISO consultant, Emergo Consulting Group, is assisting with both the ISO and CE Mark, as well as introducing these products to their distribution partners for export in these countries.

In addition to ISO Certification, the company expects to have in place its GSA contract with various government sectors including VA Hospitals and the Department of Defense in 3-4 weeks.

"Emergo Consulting Group will provide us with the outcome of the MEDICA exhibit in Germany, and this will be provided in a news release later this week. The Oxyview Nasal Cannula has received serious interest from institutional buyers, oxygen providers and suppliers, and patients. Sales have been made to all of these sectors in the past 2 months, and interest continues to grow," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

http://www.moneychannel.tv/scas.php

http://www.swivel.com/data_sets/show/1016323

http://www.copd-international.com/library/statistics.htm

www.ingen-tech.com

About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adults, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company’s operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company’s periodic filings with the U.S. Securities and Exchange Commission.

Ingen Technologies, Inc. Jeff Morgan 909-790-7180 www.info@ingen-tech.com

Ingen Enters Hospital and Therapy Markets With Expected Revenue Increase

YUCAIPA, Calif., Nov. 20, 2009 (GLOBE NEWSWIRE) — Ingen Technologies, Inc. (Pink Sheets:IGNT – News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the company is now marketing direct to the hospital and therapy respiratory markets. Ingen’s CEO, Scott Sand, will discuss these new markets this coming Tuesday, November 24, 2009 at 11:34AM eastern standard time on The Money Channel’s American Scene Radio with host Steve Crowley.

Ingen Receives $100K Purchase Order Today for New Oxyview Nasal Cannula

YUCAIPA, Calif., Nov. 4, 2009 (GLOBE NEWSWIRE) — Ingen Technologies, Inc. (Pink Sheets:IGNT – News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the company has received a purchase order from MedOx Corporation for 40,000 new Oxyview Nasal Cannulas in value of $100,000.

Ingen Announces Projections of $10M in Sales for 2010

INGEN TECHNOLOGIES, INC. (IGNT)

Ingen, Inc. manufactures medical devices and provides related services for medical and consumer markets primarily in the United States.
 

· Lincare Holdings Inc. (Lincare) is a provider of oxygen and other respiratory therapy services to patients in the home. Lincare’s customers suffer from chronic obstructive pulmonary disease (COPD), such as emphysema, chronic bronchitis or asthma, and require supplemental oxygen or other respiratory therapy services in order to alleviate the symptoms and discomfort of respiratory dysfunction. Lincare primarily provides oxygen and other respiratory therapy services to patients in the home. NASDAQ:LNCR Recent Price: $.22.68

· American Homepatient, Inc. provides home healthcare services and products consisting primarily of respiratory therapy services, home infusion therapy services, and the rental and sale of home medical equipment and home health care supplies. The Company’s services and products are paid for primarily by Medicare, Medicaid, and other third-party payors. OTCBB:AHOM Recent Price: $.210

Current Projects

Ingen Brings Aboard Leading OEM Partner for Australia

Ingen Technologies, Inc., recently announced that Medical Industries Australia has signed an OEM contract with Ingen. Approximately 1,000 COPD patients, each day, occupy a public hospital bed in Australia (at a cost of $580 per day). In many cases it’s due to an exacerbation requiring a respiratory investigative review with new titration and oxygen therapy needs established. Approximately 30,000 patients use Oxygen concentrators on a daily basis. Medical Industries Australia is a leading provider of sterile and non-sterile medical products, training and maintenance services for more than 20 years.

Ingen Cuts Manufacturing Costs and Increases Its Margins

Ingen Technologies, Inc. recently received a proposal from a leading manufacturer to help reduce production costs and material costs by 50% for the manufacture of the Oxyview and the Oxyview Nasal Cannula. Now that they are selling their respiratory products, and sales have escalated, they must reduce their cost of goods sold in order to increase their profit margins and decrease the costs to their dealers and buyers. This change will give the company a stronger foot-hold in the market. The company has a proprietary product and there is nothing in the marketplace that can compete with their device.

Company Overview

Ingen, Inc . (OTC.PK: IGNT)

Ingen’s Mission: Their Commitment to Customers

Ingen is committed to meeting the needs of our customers through ongoing product innovation and support. Ingen distributes its products through a national distributor network domestically and in Canada, Asia and European Communities. Ingen’s commitment to customers continues beyond the sale of our product.

The Beginning

Ingen, originally a privately owned company founded for the purpose of providing medical solutions for our growing healthcare market, is now a publicly traded company and growing medical device manufacturer. In 1999, Ingen founders invested several millions of dollars in the research and development of state-of-the-art respiratory monitoring devices, with a focus on helping patients and preventing unnecessary costs to the healthcare system. With multiple patents, FDA classification and certifications, Ingen is the largest manufacturer of gravity-independent in-line oxygen flow meters, meeting the demand of the growing patient population and service providers. Our products are manufactured in the USA.

Their Capabilities

We are proud of our capabilities in gas flow-meter technology and wireless digital data transfer of gas flow rate processing. Ingen is the first company to patent and develop transducers that detect oxygen flow rate and provide data transfer. This has revolutionized the oxygen therapy market providing user friendly solutions in monitoring oxygen levels and oxygen delivery systems.

Author Sanford Holst in “Moringa, Nature’s Medicine Cabinet,” writes,

"…it is said the Moringa tree prevent 300 diseases. Ancient Roman, Greek and Egyptian civilizations used…the (Moringa Tree)…It is best known as an excellent source of nutrition and a natural energy booster. Loaded with nutrients, vitamins and amino acids, it replenishes your body and provides what you need to through a hectic weekday or active weekend…" It produces long-lasting energy without hyperactivity…a nerve system at rest…a blood system not under pressure…a gland and hormone system in balance."

An L.A. Times article said,

Scientifically speaking, Moringa sounds like magic. It can rebuild weak bones, enrich anemic blood and enable a malnourished mother to nurse her staving baby. Doctors use it to treat diabetes in West Africa and high blood pressure in India…And, it’s not only good for you, it’s delicious." Mark Fritz, L.A. Times.

NUTRITION AND ENERGY BOOST
While most people notice an energy boost right away, the nutritional results with undernourished people is staggering, (See www.treesforlife.org for studies).
DETOXIFICATION
In vitro studies show the Moringa’s ability to remove putrid waste from water. This is important for the planet. Over 6 million children are believed to die each year from infections caused by unclean water. It helps our bodies detoxify in much the same way.
ANTIBIOTIC
Moringa works as a gentle, natural antibiotic,
See Eilert, U.,B. Wolters and A. Nahrstedt. “The antibiotic principle of seeds of Moringa oleifera and Moringa stenopetala.” Journal of Medicinal Plant Research, 42, pp 55-61. 1981
SKIN TREATMENT
And, like Aloe Vera, Moringa is believed to have great healing benefits for the skin. Most of the research is on topical applications, but the healing properties would extend to the body itself.
ANTI-INFLAMMATORY
Indian traditional medicines have long used the Moringa in treating the body’s inflammation. See, Udupa, S.L., A.L. Udupa and D.R. Kulkarni, “Studies on the anti-inflammatory and wound healing properties of Moringa oleifera and Aegle marmelos. Fitoterapia 65(2) pp 119-123.
ULCERS
The anti-ulcer effect of Moringa was reported in 1995 in Phytotherapy research. An extract was taken from dried leaves and showed an impressive ability to heal ulcers in lab animals. Holst, p17.
DIABETES
An extract from the Moringa leaf has been shown to be effective in lowering blood sugar levels with a space of 3 hours. Holst, pp17-18.
SLEEP
The leaf of the Moringa has been shown to aid in a calmer nervous system providing an improving in sleep. Holst, p18

In short some studies have proved Moringa leaves effective for treating,

Blood pressure
Diabetes
Colitis and Diarrhea
Used as a diuretic
Headache
Glandular swelling
Skin antiseptic
Fevers

Seeds are used for,

Scott R. Sand              Chief Executive Officer and Chairman of the Board
Thomas J. Neavitt        Chief Financial Officer
J.R. Marple                 Senior Accountant
Ron Mitchell                Certified Public Accountant
William Denney           Auditor- Child, Van Wagoner and Bradshaw LLC
Christopher A. Wirth   Chief Operations Officer & Director
Bradley C. Klearman   Director and EVP of Sales & Distribution
David Wald                 Office Manager
John Finazzo, MD        Director and Chairman of the Medical Advisory Board
Stephen O’Hara, MD  Director and Member of the Medical Advisory Board
Peter Wilke                 Attorney
Donn Harms                Patent Attorney
Robert H. Sand           Chief Manufacturing Engineer
Richard Campbell        Product Design & Engineering

News Headlines

• Ingen Enters Hospital and Therapy Markets With Expected Revenue Increase  GlobeNewswire  (Fri 4:15pm)
• Ingen Will Exhibit the Oxyview Nasal Cannula at AARC  GlobeNewswire  (Mon, Nov 16)
• INGEN TECHNOLOGIES, INC. Files SEC form 8-K, Other Events  EDGAR Online  (Thu, Nov 12)
• Ingen Brings Aboard CDM Capital to Assist With SEC Reporting Obligations  GlobeNewswire  (Tue, Nov 10)
• Ingen Receives $100K Purchase Order Today for New Oxyview Nasal Cannula  GlobeNewswire (Wed, Nov 4)
• Ingen Announces Projections of $10M in Sales for 2010  GlobeNewswire (Tue, Nov 3)
• Ingen CEO Live Radio Interview Friday With The Money Channel  GlobeNewswire  (Tue, Nov 3)
• Ingen CEO Live Radio Interview Tomorrow With The Money Channel  GlobeNewswire  (Mon, Nov 2)
• Ingen Engages New SEC Auditing Firm  GlobeNewswire  (Fri, Oct 30)
• Ingen CEO Live Radio Interview Today With The Money Channel  GlobeNewswire  (Tue, Oct 27)

WillyWizard.com owned by First Alert Financial LLC is referred to herein collectively as the "LLC Company" when the context of the statements pertain to compensation matters, including our "Compensation Disclosure" section that seeks to comply with Section 17(b) of the Securities Act of 1933, as amended, which states that any person who disseminates publications or other communications (through interstate commerce) for consideration received or to be received, directly or indirectly, from an issuer, underwriter, or dealer, must disclose the receipt and amount, whether past or prospective, of such consideration.

PLEASE NOTE: The LLC Company/WillyWizard.com and/or its affiliates are not registered as Investment Advisors in any jurisdiction whatsoever.

Release of Liability: Through use of WillyWizard.com’s email services and website you agree to hold the LLC Company/WillyWizard.com, its operators, owners, and employees harmless and completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. The LLC Company/WillyWizard.com and/or its affiliates may from time to time have positions in the securities mentioned herein, may increase or decrease such positions without notice, and may profit from such transactions.  The hiring party may have shares and may liquidate, which may affect the stock’s price. Any opinions expressed are subject to change without notice. The LLC Company/WillyWizard.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice.

Please read our full disclaimer at http://www.willywizard.com

The LLC Company has been compensated four thousand dollars by Oceaninc for a one week  (11/21 – 11/27) IGNT image marketing advertisement at WillyWizard.com.

The Publisher has previously been compensated nine thousand five hundred dollars for a  IGNT image marketing advertisement at WillyWizard.com.

Section 17 of the Securities Act of 1933, which covers Fraudulent Interstate Transactions, and specifically 17-(b) which reads as follows:

"Use of interstate commerce for purpose of offering for sale. It shall be unlawful for any person, by the use of any means or instruments of transportation or communication in interstate commerce or by the use of the mails, to publish, give publicity to, or circulate any notice, circular, advertisement, newspaper, article, letter, investment service, or communication which, though not purposing to offer a security for sale, describes such security for a consideration received or to be received, directly or indirectly, from an issuer, underwriter, or dealer, without fully disclosing the receipt, whether past or prospective, of such consideration and the amount thereof"

©2000-2009 WillyWizard.com owned by First Alert Financial LLC